Lookonchain APP

App Store

Binance Alpha Launches Acurast (ACU)

2026.01.20 18:01:15

On January 20, Binance Alpha has launched a new token—Acurast (ACU)—per official sources, with the token currently trading at $0.124.
Relevant content

Circle announces the acquisition of Singapore-based payment infrastructure firm Tazapay.

Circle announced it has signed a definitive agreement to acquire Tazapay, a Singapore-based B2B cross-border payments infrastructure company. The transaction is expected to close in 2027, subject to customary closing conditions and regulatory approvals, including clearance from the Monetary Authority of Singapore. Circle noted that Tazapay brings over $25 billion in annualized payment volume, more than 60 banking and fintech partners, and local payment rails spanning over 100 markets. Approximately 60% of Tazapay’s transaction volume already involves stablecoins. Circle added that the acquisition will enhance its global payment capabilities and drive adoption of USDC in cross-border commercial payments.

1 seconds ago

Upbit will list HEMI and USELESS

Upbit will list HEMI and USELESS trading pairs against BTC and USDT.

1 seconds ago

Solana ecosystem meme coin USELESS posts a short-term rally, surging past $280 million in market capitalization.

According to GMGN data, Solana ecosystem meme coin USELESS has rallied to a market cap exceeding $280 million, boosted by its listing on Upbit’s spot trading platform. The token has gained over 12% in the past 24 hours, with a 24-hour trading volume of $22 million. On September 1, prominent trader "Bonk Guy" noted that his bullish stance on USELESS is even stronger than when he traded BONK in 2023, adding that USELESS previously rose from a roughly $4 million market cap to $450 million during a non-bull market cycle, and could see even larger upside if it enters a genuine bull market for the first time. BlockBeats reminds users that most meme coins lack real utility, are highly volatile, and investors should exercise caution.

1 seconds ago

Yilihua: Choices in the crypto space are critical, as those who select investments and contracts experience more failures than successes.

Liquid Capital founder Yi Lihua stated that since entering the crypto space in late 2015, over a decade of experience has shown that choice is just as critical as hard work for success in the sector. He outlined three groups that have achieved notable results: 1) Bitcoin (BTC), Ethereum (ETH) and BNB holders, including those engaged in mining, hodling and mining pools, who gain from time-driven compound returns; 2) Participants in trading infrastructure, such as quantitative arbitrage firms, crypto exchanges and stablecoin projects; 3) Project teams and market makers (MM), who focus on issuing and managing assets. Conversely, Yi noted that investors and derivatives (contract) traders overall have more failures than successes, describing their approach as akin to daily hunting—requiring constant effort to generate returns, with high risks, low yields and limited compounding effects.

1 seconds ago

Binance to delist OPEN/FDUSD, SAGA/FDUSD, and VELODROME/USDC spot trading pairs

Binance will delist the following spot trading pairs and halt trading on them at 11:00 (GMT+8) on September 11, 2026: OPEN/FDUSD, SAGA/FDUSD, and VELODROME/USDC. The spot trading bot services for these pairs will also be terminated simultaneously, with users advised to update or cancel relevant operations in advance.

1 seconds ago

Insilico Medicine’s AI-developed drug detects anti-aging signals in human trials, with six aging clocks all showing a reduction in biological age.

Beating AI News Brief: Biotech firm Insilico Medicine has published new research in *Nature Biotechnology*. The study analyzed phase IIa clinical data for Rentosertib, an AI-designed drug developed by the company, and found that treated patients showed signals of reduced biological age across six protein-based aging clocks. Rentosertib is primarily used to treat idiopathic pulmonary fibrosis. The research analyzed blood samples collected from 42 patients at four time points over 12 weeks, estimating "biological age" based on changes in thousands of proteins. The treatment group as a whole trended toward younger biological age, while the placebo group showed little to no change or a slight increase. The group taking 30mg twice daily had the most consistent signals. However, this does not yet prove the drug can actually reverse aging or extend lifespan. All study participants were patients with pulmonary fibrosis, and the sample size was small. The paper’s authors note that it is currently impossible to fully distinguish whether these changes stem from anti-aging effects or improvements related to treating pulmonary fibrosis. Confirming genuine anti-aging effects will require further validation in healthy populations.

1 seconds ago

Popular tokens

BitcoinEthereumHyperliquidSolanaTRONBNBTetherAaveXRPPepeFartcoinOndoJupiterUniswapBonkPendleEthenaArbitrumAvalancheLidoChainlinkPolygonDogecoinCardano